A research consortium has created a new class of photoswitchable drugs that restore light sensitivity in animal models of retinal degeneration without requiring genetic modification.
Key facts
- •Retinal degeneration disorders like AMD and RP affect approximately 200 million people globally.
- •The prosthe6 compounds target ON-bipolar neurons to restore light sensitivity in the retina.
- •The treatment restored natural light-avoidance behavior in blind mice without requiring training.
- •The drugs function under normal daylight and indoor illumination levels.
- •The research findings were published in the Journal of the American Chemical Society.
A research consortium led by the Institute for Bioengineering of Catalonia has developed a new class of small-molecule drugs capable of restoring visual function in blind animal models. The compounds, known as prosthe6, act as molecular prostheses that allow the retina to detect light after photoreceptor cells have deteriorated. These drugs can be delivered via eye drops or injection and function under ordinary illumination levels, potentially offering a non-invasive alternative to current vision-restoration technologies.
By the numbers
Mechanism of Action
The treatment utilizes photopharmacology, where a light-sensitive molecular switch is incorporated into the drug's chemical structure. When light enters the eye, these molecules change shape to trigger signaling within the retina's surviving ON-bipolar neurons. By targeting the mGlu6 protein, the drugs effectively substitute for the function of lost photoreceptors, allowing the eye to process visual information without the need for implanted hardware or genetic therapy.
Experimental Results
In studies involving blind mice and zebrafish, the compounds restored innate light-avoidance behaviors and saccadic eye movements. The treatment was effective under standard indoor and outdoor lighting conditions, meaning no specialized light amplification was required. Researchers noted that the compounds do not cure the underlying cause of degeneration but provide a reversible, patient-friendly method to restore sight.
Future Development
The technology is currently patented, and the research team is working with a spin-off company, Eyelumina, to secure investment for further development and clinical trials. While the process of moving to human therapy remains ongoing, the researchers aim to refine the safety and duration of the treatment to provide a widely accessible option for patients with advanced retinal disorders.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by ScienceDaily.
